随着四大跨国疫苗企业辉瑞、葛兰素史克(GSK)、默沙东、赛诺菲陆续发布2024年业绩,21世纪经济报道记者依据披露的部分疫苗大单品数据,初步统计发现,2024年相关疫苗产品营收合计511.14亿美元,较2023年下滑1.44%。 从营收排名看,剔除新冠疫苗产品,Gardasil/Gardasil9(HPV疫苗)、Prevnar13/20(肺炎球菌疫苗)、Shingrix(带状疱疹疫苗)、PPH(...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.